Activities of antifolate, antiviral, and other drugs in an immunosuppressed rat model of Pneumocystis carinii pneumonia
about
sameAs
Treatment of experimental pneumocystosis: review of 7 years of experience and development of a new system for classifying antimicrobial drugsAlbendazole inhibits Pneumocystis carinii proliferation in inoculated immunosuppressed miceSynergistic combinations of Ro 11-8958 and other dihydrofolate reductase inhibitors with sulfamethoxazole and dapsone for therapy of experimental pneumocystosis6,7-disubstituted 2,4-diaminopteridines: novel inhibitors of Pneumocystis carinii and Toxoplasma gondii dihydrofolate reductaseClinically used antimicrobial drugs against experimental pneumocystosis, singly and in combination: analysis of drug interactions and efficaciesImmunodeficient and immunosuppressed mice as models to test anti-Pneumocystis carinii drugsEchinocandin treatment of pneumocystis pneumonia in rodent models depletes cysts leaving trophic burdens that cannot transmit the infectionTherapeutic potential of caspofungin combined with trimethoprim-sulfamethoxazole for pneumocystis pneumonia: a pilot study in miceRegulation of surfactant phosphatidylcholine secretion from alveolar type II cells during Pneumocystis carinii pneumonia in the rat.Relationship between mutations in dihydropteroate synthase of Pneumocystis carinii f. sp. hominis isolates in Japan and resistance to sulfonamide therapy.Population structure of rat-derived Pneumocystis carinii in Danish wild ratsIn vitro activities of pentamidine, pyrimethamine, trimethoprim, and sulfonamides against Aspergillus speciesFunctional characterization of the Pneumocystis jirovecii potential drug targets dhfs and abz2 involved in folate biosynthesisSulfa use, dihydropteroate synthase mutations, and Pneumocystis jirovecii pneumonia.Dihydropteroate synthase gene mutations in Pneumocystis and sulfa resistance.Towards new antifolates targeting eukaryotic opportunistic infectionsMutations of Pneumocystis jirovecii dihydrofolate reductase associated with failure of prophylaxis.Efficacy of sulfamethoxypyridazine in a murine model of Pneumocystis carinii pneumonia.Detection of Pneumocystis carinii and characterization of mutations associated with sulfa resistance in bronchoalveolar lavage samples from human immunodeficiency virus-infected subjects.Mutations in the Pneumocystis jirovecii DHPS gene confer cross-resistance to sulfa drugs.Life cycle, cytology, and morphology of Polypodium hydriforme, a coelenterate parasite of the eggs of acipenseriform fishes.Dihydropteroate synthase gene mutation rates in Pneumocystis jirovecii strains obtained from Iranian HIV-positive and non-HIV-positive patients.A mouse model for glucocorticoid-induced osteonecrosis: effect of a steroid holiday.Anticancer agents against malaria: time to revisit?Evaluation of sulfa drugs against recombinant Pneumocystis carinii dihydropteroate synthetase and in vivo.Cell wall antigens of Pneumocystis carinii trophozoites and cysts: purification and carbohydrate analysis of these glycoproteins.Rapid detection of dihydropteroate polymorphism in AIDS-related Pneumocystis carinii pneumonia by restriction fragment length polymorphism.
P2860
Q28316964-8FC8C2A7-A038-4147-9D27-A9BCC750AB48Q28369147-52D0DF5C-242C-47A1-B3D7-F22958E3EDC4Q28378586-AE155DDF-0E05-4799-A539-F63C12881468Q28378995-CDD17B5C-8058-4ADC-B84E-7C542845BB53Q28379455-A57AF498-F348-4FDB-B9EC-B2AB771188F8Q28379457-F4DB3E2B-1F69-4CF6-A63D-62C250C3C9AEQ28472713-3DAE1563-8A6B-45D5-B1F2-408A3D5C1AADQ28535112-3F75EBEC-B930-4839-BC35-8C918B853A46Q33909879-FCE77890-B47F-47CC-A038-9FB2D7698D5AQ33969487-8CA2E592-0B33-4040-83C1-FBF4D2417ED5Q33988101-7ED526A0-FD05-4697-8ADB-61E5EDE62E91Q34109528-C18171B5-6969-4157-BF5C-FBE31D32C337Q35385810-EF431019-8B5E-4F3E-8BEC-E87B33DB7636Q35880711-236A71DA-3082-4A39-B44F-346E6B37CD61Q35880756-02B032A8-5F1B-43A2-AF42-E939D0B6B27FQ37158762-8E5983DD-04B9-4436-AA48-3FE16BCE1CCFQ37598743-B80C18E8-540B-444D-BD39-F86FA735864AQ39557515-C9DA1EBB-BCD3-495F-85E2-64E77D20FB94Q39758104-1340E437-510F-4AEC-8A50-00998D1A2924Q40450855-531C3F14-01D7-4B2D-B0B1-DECC2DAF6B07Q40620935-2057E788-B2CC-4B2A-BDAF-621E1E777EBAQ41516189-D8479985-5C9C-4FAA-ADD7-0AC3E526BA84Q41821365-CFD6E508-D60C-493E-BD9A-67CEE331D824Q42488257-3A98C208-703F-4FC6-BE8C-81EB6843F0C2Q42553843-C82349D3-BE86-4C66-B8AC-B9822749C01FQ47970917-2887F44D-303A-45FD-AB9E-6E8564D76109Q54031895-638EA856-9FA5-469E-93D9-4478D66B9AB7
P2860
Activities of antifolate, antiviral, and other drugs in an immunosuppressed rat model of Pneumocystis carinii pneumonia
description
1992 nî lūn-bûn
@nan
1992 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
1992 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
1992年の論文
@ja
1992年論文
@yue
1992年論文
@zh-hant
1992年論文
@zh-hk
1992年論文
@zh-mo
1992年論文
@zh-tw
1992年论文
@wuu
name
Activities of antifolate, anti ...... Pneumocystis carinii pneumonia
@ast
Activities of antifolate, anti ...... Pneumocystis carinii pneumonia
@en
Activities of antifolate, anti ...... Pneumocystis carinii pneumonia
@nl
type
label
Activities of antifolate, anti ...... Pneumocystis carinii pneumonia
@ast
Activities of antifolate, anti ...... Pneumocystis carinii pneumonia
@en
Activities of antifolate, anti ...... Pneumocystis carinii pneumonia
@nl
prefLabel
Activities of antifolate, anti ...... Pneumocystis carinii pneumonia
@ast
Activities of antifolate, anti ...... Pneumocystis carinii pneumonia
@en
Activities of antifolate, anti ...... Pneumocystis carinii pneumonia
@nl
P2093
P2860
P356
P1476
Activities of antifolate, anti ...... Pneumocystis carinii pneumonia
@en
P2093
P D Walzer
P2860
P304
P356
10.1128/AAC.36.9.1935
P407
P577
1992-09-01T00:00:00Z